Access Pains After Approval In China? Consider The 'Three Ps'
Executive Summary
Still a largely self-pay market, China is in the middle of a new drug approvals rush with 48 clearances in 2018 and more pending, forcing manufacturers to innovate their access models. Among several emerging strategies, a "Three P" combination of pricing, private insurance and patient assistance seems to be winning the day.
You may also be interested in...
10 Commercial Trends To Watch In China in 2020
2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.
China's Hengrui Halts Most Generic Development
China’s favorite domestic drug maker seems to have a warning for the industry - innovate or halt. After the recent round of “4+7” centralized procurement saw some off-patent drugs priced at pennies, the leading Chinese firm Hengrui has decided to halve its generics portfolio to focus on innovative new drugs.
Hengrui Halts Most Generic Development After Prices Free Fall In China
China’s favorite domestic drug maker seems to have a warning for the industry - innovate or halt. After the recent round of “4+7” centralized procurement saw some off-patent drugs priced at pennies, the leading Chinese firm Hengrui has decided to halve its generics portfolio to focus on innovative new drugs.